Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

NMDAR-antibody encephalitis is an autoimmune brain condition caused by patient’s own antibodies that bind to NMDA (N-Methyl-D-Aspartate) receptors in the synapses between nerve cells.

Laboratory studies have shown that these antibodies can cause NMDA receptors to be removed from the cell surface into the cell, interfering with signals between them.

But a new study has now shown this directly in patients with this condition.

The research, led by UCL working with a team from Oxford, involved specialised PET-magnetic resonance scans on five people recovering from the condition and 29 healthy volunteers.

It found that in the early phase of recovery the receptors are not as available in affected patients, but came back to normal levels after full recovery in another patient.

The paper has been published in JAMA Neurology and authored by a team including researchers from Oxford University’s Nuffield Department of Clinical Neuroscience (Professor Sarosh Irani) and the Department of Psychiatry (Dr Adam Al-Diwani).

Dr Al-Diwani said:


“Understanding the effect on receptors helps inform our understanding of how the antibodies cause the condition, and may help improve treatments in the future.”

Symptoms of NMDAR-antibody encephalitis include changes in mental state that can be confused with a psychiatric illness, before patients develop seizures and a movement disorder.

Similar stories

New insights into chemogenetic designer drugs to enhance our study of behaviour

A collaborative team of researchers in DPAG and Pharmacology led by Dr Lukas Krone have uncovered striking new data demonstrating that two widely used designer drugs used to turn populations of neurons on and off in the brain cause unexpected effects on sleep. These results demonstrate a critical need to improve chemogenetic approaches in behavioural studies.

Ensuring LGBTQI+ people are treated fairly in mental health data

Andrey Kormilitzin outlines a new participatory study aimed at improving AI to take account of LGBTQI+ people so that their needs are better met by mental health services.

Community play packs inspire families to be more playful at home

A project led by Alex Hendry working with Oxford Brookes has engaged with parents and early years practitioners in a bid to help families spend more time playing with their children.

Major trials to test effectiveness of cannabidiol on psychosis

Global study involving three clinical trials will investigate the effectiveness of cannabidiol (CBD) in treating people with psychosis or psychotic symptoms, thanks to a multi-million pound grant to Oxford University.

Friendship and mental health in adolescents

Tanya Manchanda's new paper investigates the role of friendship on the mental health outcomes of adolescents